These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 15524492)

  • 21. Epoetin alfa and epoetin beta: new indication. Treatment of anaemia due to cytotoxic chemotherapy.
    Prescrire Int; 2002 Apr; 11(58):39-43. PubMed ID: 11987310
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anaemia and its functional consequences in cancer patients: current challenges in management and prospects for improving therapy.
    Demetri GD
    Br J Cancer; 2001 Apr; 84 Suppl 1(Suppl 1):31-7. PubMed ID: 11308272
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Probabilistic cost-minimisation analysis of darbepoetin alpha versus epoetin alpha in treating anaemia secondary to chronic renal failure. Assessment in Spanish clinical practice.
    Sanz-Granda A
    Farm Hosp; 2009; 33(4):208-16. PubMed ID: 19712609
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical and economic impact of epoetin in adjuvant-chemotherapy for breast cancer.
    Fagnoni P; Limat S; Chaigneau L; Guardiola E; Briaud S; Schmitt B; Merrouche Y; Pivot X; Woronoff-Lemsi MC
    Support Care Cancer; 2006 Oct; 14(10):1030-7. PubMed ID: 16802128
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biosimilar epoetins.
    Macdougall IC
    Nephrol Dial Transplant; 2009 May; 24(5):1698-9; author reply 1699-700. PubMed ID: 19366858
    [No Abstract]   [Full Text] [Related]  

  • 26. Anemia in cancer and critical care patients: pharmacoeconomic considerations.
    Reeder CE
    Am J Health Syst Pharm; 2007 Feb; 64(3 Suppl 2):S22-7; quiz S28-30. PubMed ID: 17244883
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of darbepoetin alfa and epoetin alfa in clinical practice in patients with cancer-related anemia.
    Berger A; Edelsberg J; Kallich J; Oster G
    Clin Ther; 2008 Jan; 30(1):206-18. PubMed ID: 18343258
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drug utilisation and cost considerations of erythropoiesis stimulating agents in oncology patients receiving chemotherapy: observations from a large managed-care database.
    Vekeman F; McKenzie RS; Bookhart BK; Laliberté F; Duh MS; Tak Piech C; Lefebvre P
    J Med Econ; 2009 Mar; 12(1):1-8. PubMed ID: 19450059
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost analysis of erythropoietic-stimulating therapy dosing in oncology inpatients.
    Killian AD; Gupta V; Goetz AE
    Ann Pharmacother; 2006 Mar; 40(3):421-6. PubMed ID: 16507613
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Propensity score matched assessment of treatment patterns and cost of erythropoiesis stimulating agent treatment in patients with cancer receiving myelosuppressive chemotherapy.
    Tunceli O; Bailey RA; Stephenson JJ; Singer J
    J Oncol Pharm Pract; 2013 Dec; 19(4):305-14. PubMed ID: 23235918
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improvement in quality of life for cancer patients treated with epoetin alfa.
    Libretto SE; Barrett-Lee PJ; Branson K; Gorst DW; Kaczmarski R; McAdam K; Stevenson P; Thomas R
    Eur J Cancer Care (Engl); 2001 Sep; 10(3):183-91. PubMed ID: 11829381
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cancer-related anaemia management in the 21st century.
    Pronzato P
    Cancer Treat Rev; 2006; 32 Suppl 2():S1-3. PubMed ID: 16725269
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The costs of drugs used to treat myelodysplastic syndromes following National Comprehensive Cancer Network Guidelines.
    Greenberg PL; Cosler LE; Ferro SA; Lyman GH
    J Natl Compr Canc Netw; 2008 Oct; 6(9):942-53. PubMed ID: 18926103
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy.
    Quirt I; Robeson C; Lau CY; Kovacs M; Burdette-Radoux S; Dolan S; Tang SC; McKenzie M; Couture F;
    J Clin Oncol; 2001 Nov; 19(21):4126-34. PubMed ID: 11689580
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The impact of epoetin alfa on quality of life during cancer chemotherapy: a fresh look at an old problem.
    Glaspy J
    Semin Hematol; 1997 Jul; 34(3 Suppl 2):20-6. PubMed ID: 9253780
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epoetin alfa treatment results in clinically significant improvements in quality of life in anemic cancer patients when referenced to the general population.
    Cella D; Zagari MJ; Vandoros C; Gagnon DD; Hurtz HJ; Nortier JW
    J Clin Oncol; 2003 Jan; 21(2):366-73. PubMed ID: 12525531
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Cost-effectiveness of darbepoetin alpha in an every-3-weeks schedule].
    Borget I; Chouaid C; Demarteau N; Annemans L; Pujol JL
    Bull Cancer; 2008 Apr; 95(4):465-73. PubMed ID: 18495577
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The cost-effectiveness of weekly epoetin alfa relative to weekly darbepoetin alfa in patients with chemotherapy-induced anemia.
    Ben-Hamadi R; Duh MS; Aggarwal J; Henckler A; McKenzie RS; Tak Piech C
    Curr Med Res Opin; 2005 Oct; 21(10):1677-82. PubMed ID: 16238908
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Budget impact analysis of a blood saving program for urgent traumatological surgery].
    Izuel Rami M; Gómez Barrera M; Villar Fernández I; Rabanaque Hernández MJ; Cuenca Espiérrez J; García-Erce JA
    Med Clin (Barc); 2007 Jan; 128(1):7-11. PubMed ID: 17266885
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anaemia in cancer patients: pathophysiology, incidence and treatment.
    Bokemeyer C; Oechsle K; Hartmann JT
    Eur J Clin Invest; 2005 Dec; 35 Suppl 3():26-31. PubMed ID: 16281955
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.